<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01747278</url>
  </required_header>
  <id_info>
    <org_study_id>PUMCH-CTD-PCP</org_study_id>
    <nct_id>NCT01747278</nct_id>
  </id_info>
  <brief_title>Study of Trimethoprim/Sulfamethoxazole as PCP Prophylaxis in CTD Patients</brief_title>
  <official_title>The Safety and Effectiveness of Trimethoprim/Sulfamethoxazole as Pneumocystis Carinii Pneumonia (PCP) Prophylaxis in Patients With Connective Tissue Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation the efficacy and safety profile of trimethoprim/sulfamethoxazole as Pneumocystis
      carinii pneumonia (PCP) prophylaxis in Patients With Connective Tissue Diseases (CTD) treated
      with high-dose glucocorticoids and immunosuppressive agents.

      Open-labeled, randomized, prospective single-center clinical trial. Observation period of 12
      weeks.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">August 2013</completion_date>
  <primary_completion_date type="Anticipated">June 2013</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Documented PCP infection</measure>
    <time_frame>12 weeks.</time_frame>
    <description>Documented Pneumocystis carinii pneumonia infection: defined as documentation of Pneumocystis from a properly obtained specimen (induced sputum, bronchoalveolar lavage, or biopsy) in a patient with clinical manifestations compatible with PCP.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PCP-related mortality</measure>
    <time_frame>12 weeks</time_frame>
    <description>PCP-related mortality at the end of week 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>12 weeks</time_frame>
    <description>All cause mortality at the end of week 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other infections</measure>
    <time_frame>12 weeks</time_frame>
    <description>Infections other than PCP throughout the study period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PCP-related hospitalization</measure>
    <time_frame>12 weeks</time_frame>
    <description>PCP-related hospitalization throughout the study period.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Pneumonia, Pneumocystis</condition>
  <condition>Prevention &amp; Control</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients were not treated with Trimethoprim/Sulfamethoxazole (TMP/SMX).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TMP/SMX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients received Trimethoprim/Sulfamethoxazole (TMP/SMX) 80 mg/400 mg p.o. every day as PCP Prophylaxis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trimethoprim/Sulfamethoxazole</intervention_name>
    <description>Oral Trimethoprim/Sulfamethoxazole 80 mg/400mg once daily for 12 weeks.</description>
    <arm_group_label>TMP/SMX</arm_group_label>
    <other_name>Septra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-65 years with informed consent

          -  SLE, Sjögren syndrome, Polymyositis or Dermatomyositis, defined by consensus
             classification criteria

          -  concomitant high dose glucocorticoid, defined as &gt;1mg/kg/d prednisone or equivalent

          -  concomitant cyclophosphamide, cyclosporine or mycophenolate mofetil

        Exclusion Criteria:

          -  Pregnant or lactating

          -  WBC＜ 4×10^9/L，PLT＜100×10^9/L

          -  Serum ALT or AST &gt; 2 times upper limit of normal

          -  Serum creatinine &gt; 1.5 mg/dL

          -  Severe hepatic, hematological, gastrointestinal, pulmonary, cardiovascular,
             neurological, endocrine or cerebral disease

          -  Active infection, including HIV, HCV, HBV, tuberculosis or PCP

          -  concomitant antibiotics other than trimethoprim/sulfamethoxazole

          -  Patient with malignancy

          -  Drug allergy, especially trimethoprim/sulfamethoxazole
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fengchun Zhang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hua Chen, MD</last_name>
    <phone>+86-10-69158797</phone>
    <email>chenhua@pumch.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Deptment of Rheumatology, Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fengchun Zhang, MD</last_name>
      <phone>+86-10-69158794</phone>
      <email>ZhangFCcra@yahoo.com.cn</email>
    </contact>
    <investigator>
      <last_name>Fengchun Zhang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 9, 2012</study_first_submitted>
  <study_first_submitted_qc>December 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2012</study_first_posted>
  <last_update_submitted>December 9, 2012</last_update_submitted>
  <last_update_submitted_qc>December 9, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 11, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking Union Medical College Hospital</investigator_affiliation>
    <investigator_full_name>Fengchun Zhang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Pneumocystis carinii pneumonia</keyword>
  <keyword>prophylaxis</keyword>
  <keyword>trimethoprim/sulfamethoxazole</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Pneumonia, Pneumocystis</mesh_term>
    <mesh_term>Connective Tissue Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trimethoprim</mesh_term>
    <mesh_term>Sulfamethoxazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

